1. A systematic review of quality and consistency of clinical practice guidelines on the primary prevention of food allergy and atopic dermatitis
- Author
-
Elizabeth Huiwen Tham, MRCPCH, Agnes Sze Yin Leung, MRCPCH, Kiwako Yamamoto-Hanada, MD, PhD, Lamia Dahdah, MD, Thulja Trikamjee, MD, Vrushali Vijay Warad, MD, Matthew Norris, MD, Elsy Navarrete, MD, Daria Levina, MD, Miny Samuel, PhD, Andre van Niekerk, MMed (Paed), Santiago Martinez, MD, Anne K. Ellis, MD, Leonard Bielory, MD, Hugo van Bever, MD, PhD, Dana Wallace, MD, Derek K. Chu, MD, PhD, Daniel Munblit, MD, PhD, Mimi LK. Tang, MBBS, PhD, James Sublett, MD, and Gary Wing Kin Wong, MD
- Subjects
Allergy prevention ,Food allergy ,Atopic dermatitis ,Eczema ,Clinical practice guideline ,Quality ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Background and aims: With an increasing number of Clinical Practice Guidelines (CPGs) addressing primary prevention of food allergy and atopic dermatitis, it is timely to undertake a comprehensive assessment of the quality and consistency of recommendations and evaluation of their implementability in different geographical settings. Methods: We systematically reviewed CPGs from 8 international databases and extensive website searches. Seven reviewers screened records in any language and then used the AGREE II and AGREE REX instruments to critically appraise CPGs published between January 2011 and April 2022. Results: Our search identified 2138 relevant articles, of which 30 CPGs were eventually included. Eight (27%) CPGs were shortlisted based on our predefined quality criteria of achieving scores >70% in the “Scope and Purpose” and “Rigour of Development” domains of the AGREE II instrument. Among the shortlisted CPGs, scores on the “Applicability” domain were generally low, and only 3 CPGs rated highly in the “Implementability” domain of AGREE-REX, suggesting that the majority of CPGs fared poorly on global applicability. Recommendations on maternal diet and complementary feeding in infants were mostly consistent, but recommendations on use of hydrolysed formula and supplements varied considerably. Conclusion: The overall quality of a CPG for Food Allergy and Atopic Dermatitis prevention did not correlate well with its global applicability. It is imperative that CPG developers consider stakeholders’ preferences, local applicability, and adapt existing recommendations to each individual population and healthcare system to ensure successful implementation. There is a need for development of high-quality CPGs for allergy prevention outside of North America and Europe. PROSPERO registration number: CRD42021265689.
- Published
- 2023
- Full Text
- View/download PDF